• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].

出版信息

Zhonghua Jie He He Hu Xi Za Zhi. 2021 Apr 12;44(4):292-310. doi: 10.3760/cma.j.cn112147-20201109-01091.

DOI:10.3760/cma.j.cn112147-20201109-01091
PMID:33832018
Abstract
摘要

相似文献

1
[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China].《多黏菌素在中国临床优化应用的多学科专家共识》
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Apr 12;44(4):292-310. doi: 10.3760/cma.j.cn112147-20201109-01091.
2
[Chinese expert consensus on polymyxins in the clinical practice].《多黏菌素临床应用中国专家共识》
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Oct;31(10):1194-1198. doi: 10.3760/cma.j.issn.2095-4352.2019.10.003.
3
Conclusion.结论。
Adv Exp Med Biol. 2019;1145:363-364. doi: 10.1007/978-3-030-16373-0_21.
4
[Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)].《肝细胞癌癌前病变多学科诊治专家共识（2020年版）》
Zhonghua Gan Zang Bing Za Zhi. 2020 Jan 20;28(1):14-20. doi: 10.3760/cma.j.issn.1007-3418.2020.01.005.
5
[Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].[中国、日本和韩国胃肠道间质瘤诊断与治疗的异同：从专家共识到合作前景]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Sep 25;22(9):812-819. doi: 10.3760/cma.j.issn.1671-0274.2019.09.003.
6
[Expert consensus on the MDT model of pancreatic cancer in China (2020 Edition)].《中国胰腺癌多学科诊疗模式专家共识（2020版）》
Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):531-536. doi: 10.3760/cma.j.cn112152-20200310-00192.
7
[Chinese multidisciplinary expert consensus on assessment and management of vestibular migraine].[中国前庭性偏头痛评估与管理多学科专家共识]
Zhonghua Nei Ke Za Zhi. 2019 Feb 1;58(2):102-107. doi: 10.3760/cma.j.issn.0578-1426.2019.02.006.
8
Clinical use of the polymyxins: the tale of the fox and the cat.多黏菌素的临床应用：狐狸和猫的故事。
Int J Antimicrob Agents. 2018 May;51(5):700-706. doi: 10.1016/j.ijantimicag.2017.12.023. Epub 2018 Jan 3.
9
Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.用于多重耐药革兰氏阴性菌感染的新型多粘菌素衍生物的研发。
J Antibiot (Tokyo). 2017 Apr;70(4):386-394. doi: 10.1038/ja.2016.146. Epub 2017 Jan 11.
10
The use of polymyxins to treat carbapenem resistant infections in neonates and children.多黏菌素在新生儿和儿童中治疗碳青霉烯类耐药感染的应用。
Expert Opin Pharmacother. 2019 Mar;20(4):415-422. doi: 10.1080/14656566.2018.1559817. Epub 2018 Dec 21.

引用本文的文献

1
Case Report: Polymyxin E-associated reversible leukopenia.病例报告：多粘菌素E相关的可逆性白细胞减少症。
Front Immunol. 2025 Aug 14;16:1537972. doi: 10.3389/fimmu.2025.1537972. eCollection 2025.
2
Population pharmacokinetics of colistin sulfate in critically ill patients based on NONMEM.基于NONMEM法的硫酸黏菌素在危重症患者中的群体药代动力学
Sci Rep. 2025 May 26;15(1):18295. doi: 10.1038/s41598-025-03503-9.
3
Aerosolized delivery resulting in high polymyxin B concentration levels in epithelial lining fluid ensures efficacy in ventilator-associated pneumonia.
雾化给药可使上皮衬液中的多粘菌素B浓度升高，从而确保对呼吸机相关性肺炎的疗效。
JAC Antimicrob Resist. 2025 Apr 1;7(2):dlaf023. doi: 10.1093/jacamr/dlaf023. eCollection 2025 Apr.
4
Temporal Shifts in Etiological Agents and Trends in Antimicrobial Resistance of Bloodstream Infection in Southwest China from 2016 to 2023.2016年至2023年中国西南部血流感染病原体的时间变化及抗菌药物耐药性趋势
Infect Drug Resist. 2025 Mar 11;18:1367-1379. doi: 10.2147/IDR.S514966. eCollection 2025.
5
Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study.硫酸多粘菌素B和硫酸粘菌素在危重症患者中的疗效、安全性及治疗药物监测：一项真实世界回顾性研究
Front Pharmacol. 2025 Jan 3;15:1466888. doi: 10.3389/fphar.2024.1466888. eCollection 2024.
6
Antibiotic resistance and epidemiological characteristics of polymyxin-resistant .耐多药鲍曼不动杆菌的抗生素耐药性及流行病学特征。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 May 28;49(5):737-747. doi: 10.11817/j.issn.1672-7347.2024.230567.
7
Polymyxins: recent advances and challenges.多粘菌素：最新进展与挑战
Front Pharmacol. 2024 Jun 21;15:1424765. doi: 10.3389/fphar.2024.1424765. eCollection 2024.
8
Clinical Efficacy and Safety of Colistin Sulfate in the Treatment of Carbapenem-Resistant Organism Infections in Patients with Hematological Diseases.硫酸黏菌素治疗血液病患者碳青霉烯类耐药菌感染的临床疗效与安全性
Infect Dis Ther. 2024 Jan;13(1):141-154. doi: 10.1007/s40121-023-00909-8. Epub 2024 Jan 11.
9
Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.头孢他啶-阿维巴坦与多黏菌素治疗碳青霉烯类耐药肠杆菌科感染患者的比较：系统评价和荟萃分析。
Infection. 2024 Feb;52(1):19-28. doi: 10.1007/s15010-023-02108-6. Epub 2023 Oct 25.
10
Efficacy and safety of polymyxin E sulfate in the treatment of critically ill patients with carbapenem-resistant organism infections.硫酸多粘菌素E治疗碳青霉烯类耐药菌感染重症患者的疗效及安全性
Front Med (Lausanne). 2022 Dec 29;9:1067548. doi: 10.3389/fmed.2022.1067548. eCollection 2022.